Thank you for Subscribing to Life Science Review Weekly Brief
The increasing awareness about the significance of bioanalytical services has steered its seismic market growth. Prominent research suggests that the bioanalytical testing services market is expected to reach USD 3.7 billion by 2025 at a CAGR of 11.8 percent. The market growth primarily attributes to the increasing focus on the analytical testing of biologics and biosimilars, rising preferences for outsourcing analytical services, and growing R&D expenditure in the pharmaceuticals and biopharmaceutical sectors. Further, in the previous year, Europe accounted for the second-largest revenue share in the global market.
The global bioanalytical services market today can be segmented on the basis of different factors, including ‘test type’, ‘service type’, and so on. The market presents different classifications of the test types that include ADME (absorption, distribution, metabolism, and excretion), pharmacodynamics, pharmacokinetics, bioavailability, bioequivalence, and many more. Similarly, based on service type, the analytical services are grouped into discovery bioanalysis services (non-GLP services), non-clinical bioanalysis services (GLP), and clinical bioanalysis services (GLP). These significantly aid the spaces of pharmaceutical, biotechnology, contract research organization, to name a few. To execute different analytics, multiple platforms are being deployed, ranging from gas chromatography, ligand binding assays, LC/ MS, immunoassays, cell-based assays, and mass spectrometry. However, companies have realized the high costs and time invested in conducting the services in-house, which is why the predominance of bioanalytical service providers has soared quickly.
In the wake of such increasing demand for bioanalytical services, we have compiled this issue of Life Science Review to help companies achieve their goals with the right bioanalytical service provider that can drive your company to garner top-notch services to help in the drug development processes with the required analytics. Besides, the magazine comprises valuable insights from subject-matter experts, CIOs, and CXOs on the current trends, technological improvements, and innovations and portrays their expertise.
To guide you through identifying the best-matched bioanalytical service providers, Life Science Review presents to you “Top 10 Bioanalytical Services Companies in Europe - 2021.”
Artialis Group is a CRO specialized in the development of therapies and biomarkers in the field of musculoskeletal disorders, including osteoarthritis, sarcopenia, tendinopathies, and intervertebral disk degeneration. The core service of Artialis’ technological platform is the biotesting of biomarkers for musculoskeletal diseases. They exclusively offer quantification of two proprietary biomarkers, COLL2-1 and COLL2-1NO2. Those are degradative fragments of type-II collagen, classified as biomarkers of osteoarthritis. In addition, the company offers testing of any commercially available ELISA and/or multiplex kit after a strict internal validation of its performance to ensure robustness and the reproducibility of the result
Eurofins Scientific is an international life sciences company providing a unique range of analytical testing services to clients across multiple industries to make life and the environment safer, healthier and more sustainable. Eurofins works with the biggest companies globally to ensure the products they supply are safe, their ingredients are authentic, and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences, and in support of clinical studies
Dr Gilles Martin, Chairman of the Board and Chief Executive OfficerThe wide range of high-quality services is in coherence with Eurofins’ vision to provide its customers with innovative services that help them grow and enhance their drug development processes
EUROFINS
Management
Dr Gilles Martin, Chairman of the Board and Chief Executive Officer
ICON offers a full range of consulting, development and commercialisation services that enable pharmaceutical, biotechnology, medical device, and government and public health organisations to accelerate the development of drugs and devices. The company develops integrated technologies to significantly enhance the efficiency and productivity of its clients’ drug and device development programs, providing true transparency across all areas of a study. Further, ICON’s information hub, ICONIK analyses the operational, clinical, and real-world data collected during clinical development that enhances the design and delivery of projects and strengthens engagement with investigators and patients
Intravacc has an extensive track record in developing vaccines for infectious diseases, positioning the company as a leading vaccine biotech company. The core team of Intravacc is known to have assisted a number of government bodies around the world in the past in developing life-saving vaccines for diseases like polio, measles, DPT, Hib, and influenza. After its recent privatisation, Intravacc is now pushing its bounds towards a more commercial future, so that it can support international academic institutions, public health organisations (WHO, BMGF), and pharmaceutical companies to take their vaccines to late-stage clinical trials. And at the heart of these efforts lie three proprietary platforms—cell-based, OMV-based, and the conjugation platform–developed by Intravacc. These platforms are taking the mantle in helping reduce the time and cost factors while developing new vaccines
Offers drug development services, early clinical services, pharmaceutical development services, packaging and distribution services, bioanalytical services, and formulation services
NUVISAN Pharma Services
Management
Dr. Dietrich Bruchmann, CEO and Managing Partner
Arcinova, a Quotient Sciences company, delivers high-quality end-to-end solutions by combining the disciplines of chemistry, biology, and bioinformatics and provides the pharmaceutical industry with integrated and specialist services throughout the drug development pipeline. The company focuses on process, research, development, scale-up and small-scale manufacturing, including best-in-class technology, bioanalysis, regulatory, and consulting services. As a trusted partner for its customers, the firm supports their development and delivery programmes for new medicines in a timely and cost-effective manner to sustainably improve the health and wellbeing of society
SGS offers many approved tests, including cell- and Immuno ligand-based assays, as well as potency assay testing methodologies. From early phase cell bank safety assessment and product characterization to later phase method development, bioanalysis, and final phase product release, the company delivers innovative biopharmaceutical testing, biosafety, bioanalytics, and product quality control solutions for every lifecycle stage
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle. The company's innovative services range from R&D, biomarker discovery, development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) to commercial-scale manufacture. Over the past five decades, this privately-owned company has grown organically and now employs over 6,000 highly skilled personnel across 18 facilities, including Europe, the US, and Asia
LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food, and other applied markets. LGC's product catalogue includes mission-critical tools for genomic analysis and quality assurance applications valued for their performance, quality and range. The tools play a primary role in customer workflows from discovery applications to commercial manufacture and allow customers to introduce new diagnostics and therapies to market, improve research and development, optimise food production. These help to monitor and improve the quality of food, environment and consumer products
Lipotype's Lipotype Shotgun Lipidomics provides lipidomics analysis of more than 3100 lipids and absolute quantification of lipid species. This helps to identify and quantify thousands of lipids rapidly. Further, Lipotype's mass spectrometry-based technology was designed to adapt to a wide variety of sample types to reflect the diversity of research. The company's scientific curiosity steers them to continually upgrade their lipidomics technology and serve the scientific community to achieve the greater goal of life sciences a better life